These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3151075)

  • 21. Combination H1 and H2 receptor antagonist therapy in diabetic autonomic neuropathy.
    Stacpoole PW; Robertson D
    South Med J; 1982 May; 75(5):634-5. PubMed ID: 6123154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.
    Tanaka H; Yamaguchi H; Mino M
    Clin Auton Res; 1996 Aug; 6(4):189-93. PubMed ID: 8902314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cause of eyelid ptosis, orthostatic hypotension and exercise intolerance.
    Monnens L
    Acta Paediatr; 2022 Jun; 111(6):1134-1136. PubMed ID: 35202494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N; Yamamoto M; Takayama H
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
    Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of orthostatic hypotension with dihydroxyphenylserine.
    Freeman R; Landsberg L
    Clin Neuropharmacol; 1991 Aug; 14(4):296-304. PubMed ID: 1913697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R; Landsberg L; Young J
    Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of autonomic disorders in amyloidosis].
    Suzuki T
    Nihon Rinsho; 1979 Sep; 37(9):3259-65. PubMed ID: 392144
    [No Abstract]   [Full Text] [Related]  

  • 29. [Postprandial hypotension.syncope in Shy-Drager syndrome and its treatment with oral L-DOPS].
    Hasegawa Y; Koike Y; Matsuoka Y; Takahashi A
    Nihon Naika Gakkai Zasshi; 1989 Jul; 78(7):939-43. PubMed ID: 2507719
    [No Abstract]   [Full Text] [Related]  

  • 30. Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy.
    Ando Y; Gotoh T; Kawaguchi Y; Tanaka Y; Sakashita N; Ando M
    Pharmacotherapy; 1995; 15(3):345-9. PubMed ID: 7667168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy.
    Gibbons CH; Vernino SA; Kaufmann H; Freeman R
    Neurology; 2005 Oct; 65(7):1104-6. PubMed ID: 16217067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
    Yamamoto M; Ogawa N; Ujike H
    J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurogenic orthostatic hypotension with critical illness neuropathy treated with droxidopa.
    Allen BB; Charles JA; Papadopoulos E; Avila EK
    Auton Neurosci; 2016 Jul; 198():8-9. PubMed ID: 27423298
    [No Abstract]   [Full Text] [Related]  

  • 34. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract]   [Full Text] [Related]  

  • 35. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S; Quarracino C; Otero-Losada M; Rascol O
    Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of L-threo-DOPS, a norepinephrine precursor amino acid].
    Katsube J; Narabayashi H; Hayashi A; Tanaka C; Suzuki T
    Yakugaku Zasshi; 1994 Nov; 114(11):823-46. PubMed ID: 7853146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
    Yoshida M; Noguchi S; Kuramoto S
    Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA; Hewitt LA; Isaacson S
    J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
    Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency.
    Wassenberg T; Deinum J; van Ittersum FJ; Kamsteeg EJ; Pennings M; Verbeek MM; Wevers RA; van Albada ME; Kema IP; Versmissen J; van den Meiracker T; Lenders JWM; Monnens L; Willemsen MA
    J Inherit Metab Dis; 2021 May; 44(3):554-565. PubMed ID: 33034372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.